Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Lenvatinib or Vandetanib treatment on fatigue and adrenal function in patients with advanced Radioiodine refractory differentiated thyroid cancer and Medullary thyroid cancer

Next Previous
Trial Profile

Impact of Lenvatinib or Vandetanib treatment on fatigue and adrenal function in patients with advanced Radioiodine refractory differentiated thyroid cancer and Medullary thyroid cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 29 Nov 2018 New trial record
  • 31 Oct 2018 Results published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top